FY2025 EPS Estimate for Palisade Bio Increased by Analyst

Palisade Bio, Inc. (NASDAQ:PALI) – Analysts at Brookline Capital Management upped their FY2025 earnings per share estimates for shares of Palisade Bio in a research note issued to investors on Wednesday, November 12th. Brookline Capital Management analyst K. Raja now anticipates that the company will post earnings of ($0.18) per share for the year, up from their previous estimate of ($1.55). The consensus estimate for Palisade Bio’s current full-year earnings is ($12.43) per share. Brookline Capital Management also issued estimates for Palisade Bio’s Q4 2025 earnings at ($0.01) EPS, FY2026 earnings at ($0.16) EPS, FY2027 earnings at ($0.17) EPS, FY2028 earnings at ($0.20) EPS and FY2029 earnings at ($0.25) EPS.

Palisade Bio (NASDAQ:PALI) last issued its quarterly earnings data on Monday, November 10th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.06).

A number of other research firms have also recently weighed in on PALI. Citigroup reaffirmed a “buy” rating on shares of Palisade Bio in a research note on Tuesday, November 11th. Wall Street Zen upgraded Palisade Bio from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Palisade Bio in a report on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Palisade Bio has an average rating of “Hold” and a consensus price target of $16.00.

Palisade Bio Stock Up 14.4%

PALI opened at $2.14 on Monday. The stock has a market capitalization of $318.87 million, a price-to-earnings ratio of -1.01 and a beta of 1.60. The company has a 50-day simple moving average of $1.43 and a 200 day simple moving average of $1.00. Palisade Bio has a twelve month low of $0.53 and a twelve month high of $3.30.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Palisade Bio stock. Armistice Capital LLC lifted its position in Palisade Bio, Inc. (NASDAQ:PALI) by 37.4% in the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 144,764 shares of the company’s stock after purchasing an additional 39,397 shares during the period. Armistice Capital LLC owned 3.29% of Palisade Bio worth $99,000 at the end of the most recent quarter. 11.79% of the stock is owned by institutional investors and hedge funds.

Palisade Bio Company Profile

Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage.